News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Forum: Aktien User: Lirumlarum1

ImmunityBio, Inc. @ImmunityBio Folgen Today, during the 35th Annual @Piper_Sandler Healthcare Conference, we had the opportunity to participate in a fireside discussion with Director & Sr. Research Analyst, Joe Catanzaro, Ph.D. Replay of the presentation: https://bit.ly/40OoDnl https://twitter.com/immunitybio/status/1730377169581265291?s=46

ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference 28.-30. November 2023 https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-participate-35th-annual-piper-sandler-healthcare?field_nir_news_date_value[min]=

Latest Immunity Bio, Inc. Patents: https://patents.justia.com/patent/11813292

https://last10k.com/sec-filings/IBRX/0001326110-23-000147.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=sentiment&utm_term=ibrx

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity https://ir.immunitybio.com/news-releases/news-release-details/first-data-immunitybios-memory-cytokine-enriched-nk-cells-small?field_nir_news_date_value[min]=

FDA to Study ImmunityBio Cancer Drug https://labusinessjournal.com/healthcare/immunitybio/

LUGPA 2023 Annual Meeting Date: Nov. 2-4 2023 Check out @shovelstocks message on Stocktwits http://stocktwits.com/shovelstocks/message/549863066

https://classic.clinicaltrials.gov/ct2/history/NCT03228667?A=1&B=25&C=Side-by-Side#StudyPageTop

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date https://ir.immunitybio.com/news-releases/news-release-details/fda-accepts-immunitybios-bla-resubmission-complete-and-sets-new?field_nir_news_date_value[min]=

https://www.stocktitan.net/news/IBRX/fda-accepts-immunity-bio-s-bla-resubmission-as-complete-and-sets-new-nqxkdty5z3ur.html